Abstract
Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility of anti-human epidermal growth factor receptor 2 (anti-HER2) agents in the treatment of this disease, with the attendant need to identify suitable predictive biomarkers of response to treatment.
Original language | English |
---|---|
Pages (from-to) | 1097-101 |
Number of pages | 5 |
Journal | Journal of Clinical Pathology |
Volume | 64 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2011 |
Keywords
- Sensitivity and Specificity
- Chromosomes, Human, Pair 17
- Ovarian Neoplasms
- Genes, erbB-2
- Receptor, erbB-2
- Humans
- Color
- Gene Amplification
- In Situ Hybridization
- Adenocarcinoma, Mucinous
- Cohort Studies
- Immunohistochemistry
- Female